{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-102833","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.624029+00:00","generated_at":"2026-05-29T17:47:27.490237+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance","bullets":["Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.","Authorized shares reduced from 400M to 16M; issued shares from ~193M to ~7.7M.","No fractional shares issued; fractional interests rounded up to nearest whole share.","Intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.","Trading symbol remains CTXR; new CUSIP 17322U306."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-102833","json":"https://secwatch.observer/filing/0001213900-24-102833.json","markdown":"https://secwatch.observer/filing/0001213900-24-102833.md","text":"https://secwatch.observer/filing/0001213900-24-102833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/0001213900-24-102833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/ea0222380-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T17:47:27.490237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}